In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: The Losartan Intervention for Endpoint reduction study

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1541-1546

  Wachtell, Kristian ^a,b   Gerdts, Eva ^c   Palmieri, Vittorio ^d   Olsen, Michael H ^a   Nieminen, Markku S ^d   Papademetriou, Vasilios ^e   Boman, Kurt ^f   Dahlöf, Björn ^g   Aurigemma, Gerard P ^h   Rokkedal, Jens E ^a   Devereux, Richard B ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e USA   (United States)

^f UMEÅ UNIVERSITY   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

left ventricular hypertrophy; mortality; systolic performance

Indexed keywords

LOSARTAN;

AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

EID: 77954387103     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328339f943     Document Type: Article

References (39)

1. Mock MB, Ringqvist I, Fisher LD, Davis KB, Chaitman BR, Kouchoukos NT, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66:562-568.
2. Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol 1983; 51:171-176.
3. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension [published erratum appears in J Am Coll Cardiol 1994; 24:844]. J Am Coll Cardiol 1994; 23:1444-1451.
4. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259-265. (Pubitemid 26031483)
5. \+ intakes. Am J Physiol 1996; 270:H628-H637.
6. Borow KM, Green LH, Grossman W, Braunwald E. Left ventricular end-systolic stress-shortening and stress-length relations in human. Normal values and sensitivity to inotropic state. Am J Cardiol 1982; 50:1301-1308.
7. Lutas EM, Devereux RB, Reis G, Alderman MH, Pickering TG, Borer JS, et al. Increased cardiac performance in mild essential hypertension. Left ventricular mechanics. Hypertension 1985; 7:979-988.
8. Blake J, Devereux RB, Herrold EM, Jason M, Fisher J, Borer JS, et al. Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am J Cardiol 1988; 62:246-252.
9. de Simone G, Di Lorenzo L, Costantino G, Moccia D, Buonissimo S, de Divitiis O. Supernormal contractility in primary hypertension without left ventricular hypertrophy. Hypertension 1988; 11:457-463.
10. Hartford M, Wikstrand JC, Wallentin I, Ljungman SM, Berglund GL. Left ventricular wall stress and systolic function in untreated primary hypertension. Hypertension 1985; 7:97-104.
11. Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance:10yearsof follow-up.JHypertens Suppl 1996; 14:S43-S49.
12. Verdecchia P, Schillaci G, Reboldi G, Ambrosio G, Pede S, Porcellati C. Prognostic value at midwall shortening fraction and its relation with left ventricular massinsystemic hypertension.AmJCardiol 2001;87:479-482.
13. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002; 106:227-232. (Pubitemid 34761304)
14. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Corbellini C, Castellano M, et al. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients. J Hypertens 2000; 18:1651-1656.
15. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678-683.
16. Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007; 49:311-316.
17. Wachtell K, Devereux RB, Lyle PA. Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Curr Cardiol Rep 2006; 8:356-364.
18. Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 2000; 35:6-12.
19. Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlöf B, Smith G, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Am J Cardiol 2001; 87:54-60. (Pubitemid 32013084)
20. Wachtell K, Smith G, Gerdts E, Dahlöf B, Nieminen MS, Papademetriou V, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol 2000; 85:466-472.
21. Devereux RB, Bella JN, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10:74-82. (Pubitemid 32640567)
22. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
23. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, de Faire U, Fyhrquist F, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-997.
24. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, de Faire U, Fyhrquist F, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Am J Hypertens 2000; 13:899-906.
25. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 2000; 36:766-773.
26. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20:405-412. (Pubitemid 34913739)
27. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
28. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34:1625-1632.
29. Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78:61-65.
30. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103:202-209.
31. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995; 25:83-90.
32. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventricular size and function by echocardiography. Results in normal children. Circulation 1977; 56:457-462.
33. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989; 79:872-883.
34. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 1991; 83:1676-1684.
35. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362.
36. Chen C, Wang HW, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med 2003; 22:3449-3459.
37. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296:1242-1248.
38. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death-The LIFE study. Circulation 2007; 116:700-705.
39. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001; 37:1042-1048.